Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).

导出 OA

翻译打印收藏纠错

作者： Marcin,Kowanetz ^[1] ; Wei,Zou ^[2] ; Scott N,Gettinger ^[3] ; Hartmut,Koeppen ^[2] ; Mark,Kockx ^[4] ; Peter,Schmid ^[5] ; Edward E,Kadel ^[2] ; Ignacio,Wistuba ^[6] ; Jamie,Chaft ^[7] ; Naiyer A,Rizvi ^[8] ; David R,Spigel ^[9] ; Alexander,Spira ^[10] ; Fred R,Hirsch ^[11] ; Victor,Cohen ^[12] ; Dustin,Smith ^[2] ; Zach,Boyd ^[2] ; Natasha,Miley ^[2] ; Susan,Flynn ^[2] ; Vincent,Leveque ^[2] ; David S,Shames ^[2] ; Marcus,Ballinger ^[2] ; Simonetta,Mocci ^[2] ; Geetha,Shankar ^[2] ; Roel,Funke ^[2] ; Garret,Hampton ^[2] ; Alan,Sandler ^[2] ; Lukas,Amler ^[2] ; Ira,Mellman ^[1] ; Daniel S,Chen ^[2] ; Priti S,Hegde ^[2]

作者单位： Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080; kowanetz.marcin@gene.com mellman.ira@gene.com. ^[1] Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA 94080. ^[2] Medical Oncology, Yale Cancer Center, New Haven, CT 06510. ^[3] HistoGeneX, 2610 Antwerp, Belgium. ^[4] Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, United Kingdom. ^[5] Translational Molecular Pathology, MD Anderson Cancer Center, Houston, TX 77054. ^[6] Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065. ^[7] Hematology and Oncology, Columbia University, New York, NY 10027. ^[8] Sarah Cannon Research Institute, Nashville, TN 37203. ^[9] Oncology Program, Virginia Cancer Specialists, Fairfax, VA 22031. ^[10] Medical Oncology, University of Colorado Cancer Center, Denver, CO 80045. ^[11] Oncology, Jewish General Hospital, Montreal, QC, Canada H3T 1E2. ^[12]

关键词 PD-1 PD-L1 atezolizumab cancer immunotherapy checkpoints